Samsung Bioepis signs AI antibody drug technology deal with Proteina

Samsung Bioepis, a subsidiary of Samsung Biologics, is advancing its drug development capabilities through a new technology introduction agreement with Proteina, a company specializing in AI-based protein analysis. This collaboration marks a significant step in leveraging artificial intelligence for the creation of novel antibody drugs.

The agreement follows a joint national project initiated in October of the previous year. This project involved Samsung Bioepis, Proteina, and a research team led by Professor Baek Min-kyung from Seoul National University's Department of Life Sciences. The focus of that initiative was the "Development and Demonstration of Antibody Biopharmaceuticals Using AI Models."

This new contract signifies a deeper commitment to integrating AI into the antibody drug discovery process. By combining Proteina's AI expertise with Samsung Bioepis's biopharmaceutical development experience, the companies aim to accelerate the identification and creation of innovative antibody-based therapies.

The specific financial terms of the agreement have not been disclosed, reflecting a mutual understanding between the involved parties. However, the collaboration underscores a strategic investment in cutting-edge technology to enhance the pipeline of new antibody drugs.